April 2020

No Image

CBD an Essential Business: The Georgia Hemp Company Delivers

ATLANTA, April 1, 2020 /PRNewswire/ — In states like Illinois, Colorado and Oregon, hemp & cannabis-related businesses are deemed essential during the COVID-19 Pandemic. There are many reasons for this, the first and foremost reason being the healing benefits of the plant, helping people with their anxiety, pain, immune system support and much more. For the Georgia Hemp Company, this means operating during this uncertain time.


No Image

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, April 1, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation.





No Image

A Breakthrough in the Global Medical Cannabis Market: Neuraxpharm Enters the Medical Cannabis Market as the First-ever European Pharmaceutical Company to Market Medical Cannabis Products

DÜSSELDORF, Germany and TEL AVIV, Israel, April 1, 2020 /PRNewswire/ — Neuraxpharm, a leading European specialty pharmaceutical company, together with Panaxia Labs Israel (“Panaxia Israel”) (TASE: PNAX), Israel’s largest medical cannabis manufacturer, today announced it is starting to market medical cannabis products, becoming the first European pharmaceutical company to include medical cannabis products in its portfolio. Neuraxpharm, which specializes in pharmaceutical products for the central nervous system (CNS), chose Panaxia Labs Israel, Israel’s largest medical cannabis manufacturer, as its partner in a business collaboration for the manufacture, commercialization and distribution of advanced medical cannabis products in Germany, Europe’s largest and fastest-growing medical cannabis market.